Desvenlafaxine Succinate Patent Expiration
Desvenlafaxine Succinate is Used for treating depression, including maintenance treatment of major depressive disorder. It was first introduced by Pf Prism Cv
Desvenlafaxine Succinate Patents
Given below is the list of patents protecting Desvenlafaxine Succinate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Pristiq | US6673838 | Succinate salt of O-desmethyl-venlafaxine |
Feb 11, 2022
(Expired) | Pf Prism Cv |
| Pristiq | US6673838 | Succinate salt of O-desmethyl-venlafaxine |
Mar 01, 2022
(Expired) | Pf Prism Cv |
| Pristiq | US8269040 | Derivatives of venlafaxine and methods of preparing and using the same | Jul 05, 2027 | Pf Prism Cv |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Desvenlafaxine Succinate Generics
Several generic applications have been filed for Desvenlafaxine Succinate. The first generic version for Desvenlafaxine Succinate was by Alembic Pharmaceuticals Ltd and was approved on Jun 29, 2015. And the latest generic version is by Rubicon Research Private Ltd and was approved on Dec 7, 2023.
Given below is the list of companies who have filed for Desvenlafaxine Succinate generic.
1. YICHANG HUMANWELL
Yichang Humanwell Pharmaceutical Co Ltd has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Yichang Humanwell.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | Oct 1, 2018 |
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | Oct 1, 2018 |
| EQ 25MG BASE | tablet, extended release | Prescription | ORAL | AB | Oct 13, 2020 |
2. ACTAVIS LABS FL
Actavis Laboratories Fl Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Actavis Labs Fl.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | Jul 29, 2016 |
| EQ 25MG BASE | tablet, extended release | Prescription | ORAL | AB | Jul 29, 2016 |
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | Jul 29, 2016 |
3. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | Feb 16, 2016 |
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | Feb 16, 2016 |
| EQ 25MG BASE | tablet, extended release | Prescription | ORAL | AB | Aug 28, 2017 |
4. LUPIN LTD
Lupin Ltd has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Lupin Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | Jun 29, 2015 |
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | Jun 29, 2015 |
| EQ 25MG BASE | tablet, extended release | Prescription | ORAL | AB | Apr 13, 2022 |
5. INTELLIPHARMACEUTICS
Intellipharmaceutics Corp has filed for 2 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Intellipharmaceutics.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | May 7, 2019 |
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | May 7, 2019 |
6. NORVIUM BIOSCIENCE
Norvium Bioscience Llc has filed for 2 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet, extended release | Discontinued | ORAL | N/A | Jun 29, 2015 |
| EQ 50MG BASE | tablet, extended release | Discontinued | ORAL | N/A | Jun 29, 2015 |
7. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | Oct 11, 2017 |
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | Oct 11, 2017 |
| EQ 25MG BASE | tablet, extended release | Prescription | ORAL | AB | Nov 30, 2022 |
8. RUBICON
Rubicon Research Private Ltd has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Rubicon.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | Jun 29, 2015 |
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | Jun 29, 2015 |
| EQ 25MG BASE | tablet, extended release | Prescription | ORAL | AB | Dec 7, 2023 |
9. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Alembic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | Jun 29, 2015 |
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | Jun 29, 2015 |
| EQ 25MG BASE | tablet, extended release | Prescription | ORAL | AB | Sep 14, 2018 |